Anti-Diabetic Drug Market - Forecasts from 2025 to 2030

Description

The global anti-diabetic drug market is projected to grow at a CAGR of 9.33%, from US$153.176 billion in 2025 to US$229.19 billion in 2030.

The global anti-diabetic drug market is primarily driven by the increasing prevalence of diabetes, particularly Type 2 diabetes. According to the International Diabetes Foundation, the number of adults affected by diabetes was approximately 463 million in 2019 and is projected to rise to 700 million by 2045. This surge in cases is a significant factor contributing to market growth, as more individuals require treatment for diabetes across various regions13.Geographical Insights:

North America: This region is expected to maintain a substantial share of the global anti-diabetic drug market. The presence of major pharmaceutical companies and a high prevalence of diabetes, with over 100 million American adults diagnosed with diabetes or prediabetes, significantly bolster market demand. In Canada, around 90% of diabetic individuals have Type 2 diabetes, and there is a notable increase in Type 1 diabetes cases among children due to unhealthy lifestyles24.
Asia-Pacific (APAC): The APAC region is anticipated to experience significant market growth due to a continuous rise in diabetes cases in countries like China, India, and South Korea. The availability of affordable over-the-counter (OTC) anti-diabetic medications further supports this growth trend34.

Market Drivers:

1. Rising Diabetes Prevalence: The escalating number of diabetes patients globally is the foremost driver of market expansion.

2. Technological Advancements: Innovations in diabetes therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, are enhancing treatment options.

3. Government Initiatives: Efforts aimed at improving access to diabetes care and medications are also contributing to market growth.

4. Lifestyle Factors: Increasing obesity rates and sedentary lifestyles among populations are significant contributors to the rise in Type 2 diabetes56.

The combination of these factors indicates a robust growth trajectory for the anti-diabetic drug market, driven by both demographic trends and advancements in medical treatments.

Reasons for buying this report:-

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data & forecasts from 2022 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-diabetic drug market is segmented and analyzed as below:

By Diabetes Type

Type 1
Type 2

By Drug Type

Amylinomimetic drug
Biguanides
Alpha-glucosidase inhibitors
Sodium-glucose transporter (SGLT) 2 inhibitors
Others

By Route of Administration

Oral
Insulin

By Sales Channel

Prescription
Over-The-Counter (OTC)

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Spain
Italy
Others
Middle East and Africa
Saudi Arabia
Israel
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Thailand
Indonesia
Taiwan
Others

Product Code: KSI061613514

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings
3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-DIABETIC DRUG MARKET BY DIABETES TYPE

5.1. Introduction
5.2. Type 1
5.3. Type 2

6. GLOBAL ANTI-DIABETIC DRUG MARKET BY DRUG TYPE

6.1. Introduction
6.2. Amylinomimetic drug
6.3. Biguanides
6.4. Alpha-glucosidase inhibitors
6.5. Sodium-glucose transporter (SGLT) 2 inhibitors
6.6. Others

7. GLOBAL ANTI-DIABETIC DRUG MARKET BY ROUTE OF ADMINISTRATION

7.1. Introduction
7.2. Oral
7.3. Insulin

8. GLOBAL ANTI-DIABETIC DRUG MARKET BY SALES CHANNEL

8.1. Introduction
8.2. Prescription
8.3. Over-The-Counter (OTC)

9. GLOBAL ANTI-DIABETIC DRUG MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Diabetes Type
- 9.2.2. By Drug Type
- 9.2.3. By Route of Administration
- 9.2.4. By Sales Channel
- 9.2.5. By Country
  - 9.2.5.1. USA
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. South America
- 9.3.1. By Diabetes Type
- 9.3.2. By Drug Type
- 9.3.3. By Route of Administration
- 9.3.4. By Sales Channel
- 9.3.5. By Country
  - 9.3.5.1. Brazil
  - 9.3.5.2. Argentina
  - 9.3.5.3. Others
9.4. Europe
- 9.4.1. By Diabetes Type
- 9.4.2. By Drug Type
- 9.4.3. By Route of Administration
- 9.4.4. By Sales Channel
- 9.4.5. By Country
  - 9.4.5.1. UK
  - 9.4.5.2. Germany
  - 9.4.5.3. France
  - 9.4.5.4. Spain
  - 9.4.5.5. Italy
  - 9.4.5.6. Others
9.5. Middle East and Africa
- 9.5.1. By Diabetes Type
- 9.5.2. By Drug Type
- 9.5.3. By Route of Administration
- 9.5.4. By Sales Channel
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
  - 9.5.5.2. Israel
  - 9.5.5.3. UAE
  - 9.5.5.4. Others
9.6. Asia Pacific
- 9.6.1. By Diabetes Type
- 9.6.2. By Drug Type
- 9.6.3. By Route of Administration
- 9.6.4. By Sales Channel
- 9.6.5. By Country
  - 9.6.5.1. China
  - 9.6.5.2. Japan
  - 9.6.5.3. India
  - 9.6.5.4. South Korea
  - 9.6.5.5. Taiwan
  - 9.6.5.6. Thailand
  - 9.6.5.7. Indonesia
  - 9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. AstraZeneca
11.2. Pfizer Inc.
11.3. Merck & Co., Inc.
11.4. Novo Nordisk A/S
11.5. Eli Lilly and Company
11.6. Glenmark Pharmaceuticals Ltd.
11.7. Abbott
11.8. Boehringer Ingelheim International GmbH